Increased systemic toxicity of sarcoma chemotherapy due to combination with the P-glycoprotein inhibitor cyclosporin.
Theis
J G
JG
Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, The University of Toronto, Canada.
Chan
H S
HS
Greenberg
M L
ML
Malkin
D
D
Karaskov
V
V
Moncica
I
I
Koren
G
G
Doyle
J
J
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002648:Child; D003520:Cyclophosphamide / Q000008:administration & dosage; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects*; D003609:Dactinomycin / Q000008:administration & dosage; D004347:Drug Interactions; D005047:Etoposide / Q000008:administration & dosage; D005334:Fever / Q000139:chemically induced; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D009503:Neutropenia / Q000139:chemically induced; D010343:Patient Admission; D012189:Retrospective Studies; D012509:Sarcoma / Q000188:drug therapy*; D018805:Sepsis / Q000139:chemically induced; D012983:Soft Tissue Neoplasms / Q000188:drug therapy*; D014750:Vincristine / Q000008:administration & dosage
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D007166:Immunosuppressive Agents; D003609:Dactinomycin; D014750:Vincristine; D005047:Etoposide; D016572:Cyclosporine; D003520:Cyclophosphamide; D007069:Ifosfamide